Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00UVU
|
||||
| Former ID |
DIB004152
|
||||
| Drug Name |
Lipoteichoic acid
|
||||
| Synonyms |
Oncomycin; Lipoteichoic acid (cancer); Lipoteichoic acid (cancer), Lunamed; TLR-2 modulator (subcutaneous, solid tumor), LUNAMeD; Toll like receptor-2 modulator (subcutaneous, solid tumor), LUNAMeD
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1/2 | [1] | ||
| Company |
Lunamed Operations AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Toll-like receptor 2 | Target Info | Modulator | [2] | |
| KEGG Pathway | Phagosome | ||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| Legionellosis | |||||
| Leishmaniasis | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Malaria | |||||
| Toxoplasmosis | |||||
| Amoebiasis | |||||
| Tuberculosis | |||||
| Hepatitis B | |||||
| Measles | |||||
| Herpes simplex infection | |||||
| Proteoglycans in cancer | |||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| PANTHER Pathway | Toll receptor signaling pathway | ||||
| Pathway Interaction Database | Endogenous TLR signaling | ||||
| Reactome | Beta defensins | ||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| Toll Like Receptor TLR6:TLR2 Cascade | |||||
| MyD88 deficiency (TLR2/4) | |||||
| IRAK4 deficiency (TLR2/4) | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| IL1 and megakaryotyces in obesity | |||||
| Human Complement System | |||||
| Toll-Like Receptors Cascades | |||||
| MyD88:Mal cascade initiated on plasma membrane | |||||
| Defensins | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024869) | ||||
| REF 2 | Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem. 2003 May 2;278(18):15587-94. Epub 2003 Feb 19. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.